LIM-domain-only 4 (LMO4) enhances CD8+ T-cell stemness and tumor rejection by boosting IL-21-STAT3 signaling

URN to cite this document:: urn:nbn:de:bvb:355-epub-785622
DOI to cite this document:: 10.5283/epub.78562

Schelker, Roland C. ; Fioravanti, Jessica ; Mastrogiovanni, Fabio ; Baldwin, Jeremy G. ; Rana, Nisha ; Li, Peng ; Chen, Ping ; Vadász, Timea

; Spolski, Rosanne ; Heuser-Loy, Christoph ; Slavkovic-Lukic, Dragana ; Noronha, Pedro ; Damiano, Giuseppe ; Raccosta, Laura ; Maggioni, Daniela ; Pullugula, Sree ; Lin, Jian-Xin ; Oh, Jangsuk ; Grandinetti, Patrick ; Lecce, Mario ; Hesse, Leo ; Kocks, Emilia ; Martín-Santos, Azucena ; Gebhard, Claudia ; Telford, William G. ; Ji, Yun ; Restifo, Nicholas P. ; Russo, Vincenzo ; Rehli, Michael

; Herr, Wolfgang ; Leonard, Warren J. ; Gattinoni, Luca

License: Creative Commons Attribution 4.0
PDF - Published Version
(4MB)

Date of publication of this fulltext: 03 Feb 2026 07:07

Alternative links to fulltext:DOI Publisher

Details

Preview

Export bibliographical data

Abstract

High frequencies of stem-like memory T cells in infusion products correlate with superior patient outcomes across multiple T cell therapy trials. Herein, we analyzed a published CRISPR activation screening to identify transcriptional regulators that could be harnessed to augment stem-like behavior in CD8+ T cells. Using IFN-γ production as a proxy for CD8+ T cell terminal differentiation, LMO4 ...